CTI Life Sciences Fund

CTI Life Sciences Fund is a venture capital firm based in Montreal, Quebec, that invests in pre-clinical and clinical-stage biotechnology companies across Canada and North America. The firm operates as a company builder, deploying capital raised from institutional investors, including pension funds and government-backed entities, into therapeutic and modality-agnostic startups to advance drug development. The organization currently manages $345 million in total assets under management and maintains an active portfolio of 12 life sciences companies. Recently, the firm completed the first close of its third venture fund at $100 million CAD, with a final target size of up to $200 million CAD. Its investment portfolio includes notable biotechnology enterprises such as Zymeworks, VectivBio, Medicago, Ability Pharma, and enGene. CTI Life Sciences Fund was founded in 2006 by co-founder and general partner Ken Pastor.